Bps1691
Veteran Member
There is a record of 26 people using the drug. It worked out that the group was worse off using the drug than not. 26 is not even enough to start with. You need 100000 people in a double blind and controlled study. And, when you are done with that you do it again.
This will take at least 6 months if not more. Although the drug is legal, it has not be approved for this virus. This is a deadly drug and death by overdose is a real possibility. What dosage is effective for stopping the virus? What is the least amount that can be used? What about using it in tandem with another drug? How many does a day? How many days? Relapse? All of these questions (and more) need to be answered.
Interested in seeing the source for the 26 people study you mention in this post.
French researcher posts successful Covid-19 drug trial
A renowned research professor in France has reported successful results from a new treatment for Covid-19, with early tests suggesting it can stop the virus from being contagious in just six days.
www.connexionfrance.com
A renowned research professor in France has reported successful results from a new treatment for Covid-19, with early tests suggesting it can stop the virus from being contagious in just six days.
Professor Didier Raoult from infection hospital l'Institut Hospitalo-Universitaire (IHU) Méditerranée Infection in Marseille (Bouches-du-Rhône, Provence-Alpes-Côte d'Azur), published a video explaining the trials on Monday March 16.
Professor Raoult is an infectious diseases specialist and head of the IHU Méditerranée Infection, who has been tasked by - and consulted by - the French government to research possible treatments of Covid-19.
He said that the first Covid-19 patients he had treated with the drug chloroquine had seen a rapid and effective speeding up of their healing process, and a sharp decrease in the amount of time they remained contagious.
Chloroquine - which is normally used mainly to prevent and treat malaria - was administered via the named drug, Plaquenil.
The treatment was offered to 24 patients, who were among the first to become infected in the south east of France, and who had voluntarily admitted themselves to hospital for the process.
Patients were given 600mcg per day for 10 days. They were closely monitored, as the drug can interact with other medication, and cause severe side effects in some cases.
Professor Raoult said: “We included everyone who was in agreement [to be treated], which was almost everyone. Two towns in the protocol, Nice and Avignon, gave us [infected] patients who had not yet received treatment.
“We were able to ascertain that patients who had not received Plaquenil (the drug containing hydroxychloroquine) were still contagious after six days, but of those that had received Plaquenil, after six days, only 25% were still contagious.”
Chloroquine phosphate and hydroxychloroquine have previously been used to treat coronavirus patients in China, in ongoing Covid-19 clinical trials.
Kaletra, a US-based antiviral drug normally used to treat HIV, is another medicine that is being tested in the fight against Covid-19.
US academic study concurs
A new academic study, published on Friday March 13 by US scientific